Durvalumab + Oleclumab
D9108C00001
Phase 2 small_molecule completed
Quick answer
Durvalumab + Oleclumab for Stage III Non-small Cell Lung Cancer is a Phase 2 program (small_molecule) at MedImmune with 1 ClinicalTrials.gov record(s).
Program details
- Company
- MedImmune
- Indication
- Stage III Non-small Cell Lung Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed